Skip to main content
Erschienen in: Familial Cancer 1/2018

27.05.2017 | Original Article

Quality of life following prophylactic gynecological surgery: experiences of female Lynch mutation carriers

verfasst von: Holly Etchegary, Elizabeth Dicks, Laura Tamutis, Lesa Dawson

Erschienen in: Familial Cancer | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Lynch syndrome (LS) is a genetic condition conferring an elevated risk of gastrointestinal, gynecologic and other malignancies, often before the age of 50. Current guidelines recommend prophylactic gynecologic surgery to manage inherited cancers for female mutation carriers. Data is lacking on women’s quality of life following surgery. In this pilot study, we explored how women described their quality of life post-prophylactic gynecologic surgery and the factors that affected post-surgery experiences. A qualitative interview study was the chosen design. Ten female Lynch syndrome mutation carriers were interviewed by phone. Interviews were transcribed and analysed for themes relating to quality of life post-surgery using content analysis and constant comparison. Women largely reported doing well since their surgeries, though all described deleterious impacts on quality of life. Positive impacts of surgery included a reduction in cancer worry and an increase in healthy lifestyle behaviors, while negative impacts due to the sudden onset of menopause and impact on sexual function were common. Pre-surgical knowledge, drug and topical therapies, and post-surgical support all contributed to a positive quality of life. This small pilot study revealed increased endocrine symptoms and a negative impact on sexual health following prophylactic gynecological surgery. Women who were informed of potential symptoms pre-surgery coped better with surgical outcomes, as did women using some form of HRT. All women experienced reduced cancer worry post-surgery. Findings highlight areas for discussion in pre-operative settings (e.g., sexual health), as well as the need for better follow-up support post-surgery.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Stoffel E, Mukherjee B, Raymond V, Tayob N, Kastrinos F, Sparr J, Wang F, Bandipalliam P, Syngal S, Gruber SB (2009) Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 137:1621–1627CrossRefPubMedPubMedCentral Stoffel E, Mukherjee B, Raymond V, Tayob N, Kastrinos F, Sparr J, Wang F, Bandipalliam P, Syngal S, Gruber SB (2009) Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 137:1621–1627CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Aarnio M, Mecklin J, Aaltonen L, Nystrom-Lahti M, Jarvinen H (1995) Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNCC) syndrome. Int J Cancer 64:430–433CrossRefPubMed Aarnio M, Mecklin J, Aaltonen L, Nystrom-Lahti M, Jarvinen H (1995) Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNCC) syndrome. Int J Cancer 64:430–433CrossRefPubMed
3.
Zurück zum Zitat Jarvinen H, Renkonen-Sinisalo L, Aktan-Collan K, Peltomaki P, Aaltonen L, Mecklin J (2009) Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27:4793–4797CrossRefPubMed Jarvinen H, Renkonen-Sinisalo L, Aktan-Collan K, Peltomaki P, Aaltonen L, Mecklin J (2009) Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27:4793–4797CrossRefPubMed
4.
Zurück zum Zitat Lynch H, Casey M, Snyder C, Bewtra C, Lynch F, Butts M, Godwin A (2009) Hereditary ovarian cancer: molecular genetics, pathology, management and heterogeneity. Mol Oncol 3(2):97–147CrossRefPubMedPubMedCentral Lynch H, Casey M, Snyder C, Bewtra C, Lynch F, Butts M, Godwin A (2009) Hereditary ovarian cancer: molecular genetics, pathology, management and heterogeneity. Mol Oncol 3(2):97–147CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Schmeler K, Daniels M, Soliman P, Broaddus R, Deavers M, Vu T, Chang G, Lu K (2010) Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndrome. Obstet Gynecol 115(2):434–434 Schmeler K, Daniels M, Soliman P, Broaddus R, Deavers M, Vu T, Chang G, Lu K (2010) Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndrome. Obstet Gynecol 115(2):434–434
6.
Zurück zum Zitat Chapman J, Jacoby V, Chen L (2015) Managing symptoms and maximizing quality of life after preventive interventions for cancer risk reduction. Curr Opin Obstet Gynecol 27:40–44CrossRefPubMed Chapman J, Jacoby V, Chen L (2015) Managing symptoms and maximizing quality of life after preventive interventions for cancer risk reduction. Curr Opin Obstet Gynecol 27:40–44CrossRefPubMed
7.
Zurück zum Zitat Lindor NM, Gloria MP, Donald WH, Anita YK, Miesfeldt S, Karen HL (2006) Recommendations for the care of individuals with an inherited predisposition to lynch syndrome: A systematic review. JAMA 296:1507–1517CrossRefPubMed Lindor NM, Gloria MP, Donald WH, Anita YK, Miesfeldt S, Karen HL (2006) Recommendations for the care of individuals with an inherited predisposition to lynch syndrome: A systematic review. JAMA 296:1507–1517CrossRefPubMed
8.
Zurück zum Zitat McCann G, Eisenhauer E (2014) Hereditary cancer syndromes with high risk of endometrial and ovarian cancer: Surgical options for personalized care. J Surg Oncol. doi:10.1002/jso.23743 PubMed McCann G, Eisenhauer E (2014) Hereditary cancer syndromes with high risk of endometrial and ovarian cancer: Surgical options for personalized care. J Surg Oncol. doi:10.​1002/​jso.​23743 PubMed
9.
Zurück zum Zitat Auranen A, Joutsiniemi T (2011) A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta Obstet Gynecol Scand 90:437–444CrossRefPubMed Auranen A, Joutsiniemi T (2011) A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta Obstet Gynecol Scand 90:437–444CrossRefPubMed
10.
Zurück zum Zitat Stuckless S, Green J, Dawson L, Barrett B, Woods M, Dicks E, Parfrey P (2013) Impact of gynecological screening in LS carriers with an MSH2 mutation. Clin Genet 83:359–364CrossRefPubMed Stuckless S, Green J, Dawson L, Barrett B, Woods M, Dicks E, Parfrey P (2013) Impact of gynecological screening in LS carriers with an MSH2 mutation. Clin Genet 83:359–364CrossRefPubMed
11.
Zurück zum Zitat Schmeler K, Lynch H, Chen L, Munsell M, Soliman P, Clark M, White K Daniels MS, White KG, Boyd-Rogers SG, Conrad PG, Yang KY, Rubin MM, Sun CC, Slomovitz BM, Gershenson DM, Lu KH (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261–269CrossRefPubMed Schmeler K, Lynch H, Chen L, Munsell M, Soliman P, Clark M, White K Daniels MS, White KG, Boyd-Rogers SG, Conrad PG, Yang KY, Rubin MM, Sun CC, Slomovitz BM, Gershenson DM, Lu KH (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261–269CrossRefPubMed
12.
Zurück zum Zitat Vasen H, Blanco I, Aktan-Collin K, Gopie J, Alonso A, Aretz S, Bernstein I, Bertario L, Burn J, Capella G, Colas C, Engel C, Frayling IM, Genuardi M, Heinimann K, Hes FJ, Hodgson SV, Karagiannis JA, Lalloo F, Lindblom A, Mecklin JP, Møller P, Myrhoj T, Nagengast FM, Parc Y, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Sijmons RH, Tejpar S, Thomas HJ, Rahner N, Wijnen JT, Järvinen HJ, Möslein G, Mallorca Group (2013) Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations from a group of European experts. Gut 62:812–823.CrossRefPubMedPubMedCentral Vasen H, Blanco I, Aktan-Collin K, Gopie J, Alonso A, Aretz S, Bernstein I, Bertario L, Burn J, Capella G, Colas C, Engel C, Frayling IM, Genuardi M, Heinimann K, Hes FJ, Hodgson SV, Karagiannis JA, Lalloo F, Lindblom A, Mecklin JP, Møller P, Myrhoj T, Nagengast FM, Parc Y, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Sijmons RH, Tejpar S, Thomas HJ, Rahner N, Wijnen JT, Järvinen HJ, Möslein G, Mallorca Group (2013) Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations from a group of European experts. Gut 62:812–823.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Parker W, Feskanich D, Broder M, Chang E, Shoupe D, Farquhar C, Berek JS, Manson JE (2013) Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 121(4):709–716CrossRefPubMedPubMedCentral Parker W, Feskanich D, Broder M, Chang E, Shoupe D, Farquhar C, Berek JS, Manson JE (2013) Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 121(4):709–716CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Chapman J, Powell C, McLennan J, Crawford B, Mak J, Stewart N, Chen LM (2011) Surveillance of survivors: follow-up after risk reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers. Gynecol Oncol 122:339–343CrossRefPubMed Chapman J, Powell C, McLennan J, Crawford B, Mak J, Stewart N, Chen LM (2011) Surveillance of survivors: follow-up after risk reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers. Gynecol Oncol 122:339–343CrossRefPubMed
15.
Zurück zum Zitat Bonadies D, Moyer A, Matloff E (2011) What I wish I’d known before surgery: BRCA carriers’ perspectives after bilateral salpingo-oophorectomy. Fam Cancer 10:79–85CrossRef Bonadies D, Moyer A, Matloff E (2011) What I wish I’d known before surgery: BRCA carriers’ perspectives after bilateral salpingo-oophorectomy. Fam Cancer 10:79–85CrossRef
16.
Zurück zum Zitat Fang C, Cherry C, Devarajan K, Li T, Malick J, Daly MB (2009) A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecol Oncol 112:594–600CrossRefPubMedPubMedCentral Fang C, Cherry C, Devarajan K, Li T, Malick J, Daly MB (2009) A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecol Oncol 112:594–600CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Shuster L, Gostout B, Grossardt B, Rocca W (2008) Prophylactic oophorectomy in pre-menopausal women and long-term health—a review. Menopause Int 14:111–116PubMedPubMedCentral Shuster L, Gostout B, Grossardt B, Rocca W (2008) Prophylactic oophorectomy in pre-menopausal women and long-term health—a review. Menopause Int 14:111–116PubMedPubMedCentral
18.
Zurück zum Zitat Johansen N, Liavaag A, Tanbo T, Dahl A, Pripp A, Michelsen T (2016) Sexual activity and functioning after risk-reducing salpingo-oophorectomy: impact of hormone replacement therapy. Gynecol Oncol 140:101–106CrossRefPubMed Johansen N, Liavaag A, Tanbo T, Dahl A, Pripp A, Michelsen T (2016) Sexual activity and functioning after risk-reducing salpingo-oophorectomy: impact of hormone replacement therapy. Gynecol Oncol 140:101–106CrossRefPubMed
19.
Zurück zum Zitat Finch A, Metcalfe K, Chiang J, Elit L, McLaughlin J, Springate C, Demsky R, Murphy J, Rosen B, Narod SA (2011) The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 121:163–168CrossRefPubMed Finch A, Metcalfe K, Chiang J, Elit L, McLaughlin J, Springate C, Demsky R, Murphy J, Rosen B, Narod SA (2011) The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 121:163–168CrossRefPubMed
20.
Zurück zum Zitat Tucker P, Bulsara M, Salfinger S, Tan J, Green H, Cohen P (2016) Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy. Gynecol Oncol 140:95–100CrossRefPubMed Tucker P, Bulsara M, Salfinger S, Tan J, Green H, Cohen P (2016) Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy. Gynecol Oncol 140:95–100CrossRefPubMed
21.
Zurück zum Zitat Madalinska J, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir H, Massuger L, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK (2005) Quality of life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23:6890–6898CrossRefPubMed Madalinska J, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir H, Massuger L, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK (2005) Quality of life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23:6890–6898CrossRefPubMed
22.
Zurück zum Zitat Moldovan R, Keating S, Clancy T (2015) The impact of risk-reducing gynaecological surgery in premenopausal women at high risk of endometrial and ovarian cancer due to Lynch syndrome. Fam Cancer 14:51–60CrossRefPubMed Moldovan R, Keating S, Clancy T (2015) The impact of risk-reducing gynaecological surgery in premenopausal women at high risk of endometrial and ovarian cancer due to Lynch syndrome. Fam Cancer 14:51–60CrossRefPubMed
23.
Zurück zum Zitat Miller S, Roussi P, Mary B, Scarpato J (2010) New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy. Clin Cancer Res 16:5094–5106CrossRefPubMedPubMedCentral Miller S, Roussi P, Mary B, Scarpato J (2010) New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy. Clin Cancer Res 16:5094–5106CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Brotto L, Branco N, Dunkley C, McCullum M, McApline J (2012) Risk-reducing bilateral salpingo-oophorectomy and sexual health: a qualitative study. J Obstet Gynaecol Can 34:172–178CrossRefPubMed Brotto L, Branco N, Dunkley C, McCullum M, McApline J (2012) Risk-reducing bilateral salpingo-oophorectomy and sexual health: a qualitative study. J Obstet Gynaecol Can 34:172–178CrossRefPubMed
25.
Zurück zum Zitat Etchegary H, Dicks E, Watkins K, Alani S, Dawson L (2015) Decisions about prophylactic gynecologic surgery: a qualitative study of the experience of female Lynch syndrome mutation carriers. Hered Cancer Clin Pract 13(1):10CrossRefPubMedPubMedCentral Etchegary H, Dicks E, Watkins K, Alani S, Dawson L (2015) Decisions about prophylactic gynecologic surgery: a qualitative study of the experience of female Lynch syndrome mutation carriers. Hered Cancer Clin Pract 13(1):10CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Yurgelun M, Mercado R, Rosenblatt M, Dandapani M, Kohlmann W, Conrad, Blanco A, Shannon KM, Chung DC, Terdiman J, Gruber SB, Garber JE, Syngal S, Stoffel EM (2012) Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome. Gynecol Oncol 127:544–551CrossRefPubMedPubMedCentral Yurgelun M, Mercado R, Rosenblatt M, Dandapani M, Kohlmann W, Conrad, Blanco A, Shannon KM, Chung DC, Terdiman J, Gruber SB, Garber JE, Syngal S, Stoffel EM (2012) Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome. Gynecol Oncol 127:544–551CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Sandelowski M (2000) Whatever happened to qualitative description? Res Nurs Health 23:334–340CrossRefPubMed Sandelowski M (2000) Whatever happened to qualitative description? Res Nurs Health 23:334–340CrossRefPubMed
29.
Zurück zum Zitat Glaser B, Strauss A (1967) The discovery of grounded theory. Aldine, Chicago Glaser B, Strauss A (1967) The discovery of grounded theory. Aldine, Chicago
30.
Zurück zum Zitat Marchetti C, Iadarola R, Palaia I, di Donato V, Perniola G, Muzii L, Panici PB (2014) Hormone therapy in oophorectomized BRCA 1/2 mutation carriers. Menopause 21:763–768CrossRefPubMed Marchetti C, Iadarola R, Palaia I, di Donato V, Perniola G, Muzii L, Panici PB (2014) Hormone therapy in oophorectomized BRCA 1/2 mutation carriers. Menopause 21:763–768CrossRefPubMed
31.
Zurück zum Zitat Brain K, Gravell C, France E, Fiander A, Gray J (2004) An exploratory qualitative study of women’s perceptions of risk management options for familial ovarian cancer: implications for informed decision making. Gynecol Oncol 92:905–913CrossRefPubMed Brain K, Gravell C, France E, Fiander A, Gray J (2004) An exploratory qualitative study of women’s perceptions of risk management options for familial ovarian cancer: implications for informed decision making. Gynecol Oncol 92:905–913CrossRefPubMed
32.
Zurück zum Zitat Tiller K, Meiser B, Gould L, Tucker K, Dudding T, Franklin J, Friedlander M, Andrews L (2005) Knowledge of risk management strategies and information and risk management preferences of women at increased risk for ovarian cancer. Psychooncology 14:249–261CrossRefPubMed Tiller K, Meiser B, Gould L, Tucker K, Dudding T, Franklin J, Friedlander M, Andrews L (2005) Knowledge of risk management strategies and information and risk management preferences of women at increased risk for ovarian cancer. Psychooncology 14:249–261CrossRefPubMed
33.
Zurück zum Zitat Watkins K, Way, C, Fiander J, Meadus R, Esplen MJ, Green J, Ludlow VC, Etchegary H, Parfrey P (2011) Lynch syndrome: barriers and facilitators of screening and disease management. Hered Cancer Clin Pract 9:8CrossRefPubMedPubMedCentral Watkins K, Way, C, Fiander J, Meadus R, Esplen MJ, Green J, Ludlow VC, Etchegary H, Parfrey P (2011) Lynch syndrome: barriers and facilitators of screening and disease management. Hered Cancer Clin Pract 9:8CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Barrow P, Khan M, Lalloo F, Evans D, Hill J (2013) Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. Br J Surg 100(Suppl 7):123–124 Barrow P, Khan M, Lalloo F, Evans D, Hill J (2013) Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. Br J Surg 100(Suppl 7):123–124
Metadaten
Titel
Quality of life following prophylactic gynecological surgery: experiences of female Lynch mutation carriers
verfasst von
Holly Etchegary
Elizabeth Dicks
Laura Tamutis
Lesa Dawson
Publikationsdatum
27.05.2017
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 1/2018
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-017-9997-6

Weitere Artikel der Ausgabe 1/2018

Familial Cancer 1/2018 Zur Ausgabe

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.